RE:RE:PRICE LEVELjopatclo wrote: just for fun-while Cardiologs financial terms of the transaction is undisclosed, They did a financing of USD15M, assuming that that bought the venture capital fund, Alven, 10% of the company, that would peg Cardilogs ~USD150M valuation as of Jan 2020. Typically venture capital funds would avg out 30% return per year, which give Cardiologs valuation of $250M prior to takeover. Say there is another 30% premium at take over deal, Cardiologs deal would be at USD300M. This would be consistent with with GA's earlier comment about a deal worth $250M valuation if they can sell 80-100 units. we are severely undervalued by a long shot. bluemoons20 wrote: Here we are down about 50% so we should be able to have a bit of fun on the board.
The climb is going to be steep. There are probably about 5 or 6 million shares left overhanging from the financing let alone other disallusioned players. It is going to be real tough to get over 50 again for quite a while. The only thing that might make it easier is a lot of sales (and not 2 or 3 but say 100) or a buy out offer. Interesting to note in a recent article, Phillips bought a company and GE bought a company too. But no one bought VPT ???
But lets put the gloom away and just have some fun on the board until the New Year.
GLTA
While you are having fun speculating and making comparisons to Cardiolog, which has a different model and metrics, why not also consider some facts:
1. I find the interesting part is the acquisition, and what was required in terms of the database “
Cardiologs’ technology is built on a growing database of more than 20 million ECG recordings and supported by a number of clinical publications” and I read that they
treated over 1 million patients. https://www.philips.com/a-w/about/news/archive/standard/news/press/2021/20211108-philips-to-expand-its-cardiac-diagnostics-and-monitoring-portfolio-with-the-acquisition-of-cardiologs.html
So hoe does this related to VPTs customer base that is largely free "placements" and no sales over the last few reported quarters. Zero actual revenue.
2.Thgis article was actually labbelled as an advertisement, from my understanding (see below)
.
In terms of VPT, It is an eloquent restatement of things that are already known, but by linking the two-is it intended to fuel such "fun" speculations?
I am an idiot, so I need help here....
But as they state in the article
“
This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this article is not provided to any individual with a view toward their individual circumstances.
Baystreet.ca has been paid a fee of one thousand nine hundred dollars for Ventripoint Diagnostics Ltd. advertising from Castle Rising Media. T
here may be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this article as the basis for any investment decision.”